After abruptly ending its hepatitis B virus program in January, Spring Bank Pharmaceuticals (NASDAQ:SBPH) is in the early stages of examining whether its family of RIG-I agonists have the potential to attack SARS-CoV-2...
Spring Bank Pharmaceuticals (NASDAQ:SBPH) will be reporting clinical data readouts throughout 2020 as it advances a portfolio of three drug candidates for the treatment of chronic hepatitis B virus (HBV) as well as...
Spring Bank Pharmaceuticals (NASDAQ:SBPH) named Scott Smith as an independent member of the board, replacing Jonathan Bates, who is stepping down as a director after 10 years of service with the company.